KALA BIO, Inc. announced a registered direct offering of its common stock priced at $1.00 per share.
The offering is expected to close on December 5, 2025, pending customary closing conditions.
H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Offering Details
10,000,000 shares of common stock at $1.00 per share for gross proceeds of approximately $10 million.
Use of Proceeds
Repayment of indebtedness and general corporate purposes intended for the net proceeds from the offering.
Regulatory Compliance
The offering is made under a 'shelf' registration statement (File No. 333-270263) filed with the SEC.
- KALA BIO's strategic move to raise funds through a direct offering signals potential expansions or developments within the company.
- The completion of this offering may enhance KALA BIO's financial position and support its operational growth.
- Investor interest in KALA BIO may increase following the successful closure of the offering.
The registered direct offering signifies KALA BIO's proactive approach to funding strategies, positioning the company for future growth and innovation in the biopharmaceutical sector.